or Connect
HotStockMarket › Forums › HSM Stock Forum › Stock Message Boards NYSE, NASDAQ, AMEX › UNIS - Unilife Medical Solutions
New Posts  All Forums:Forum Nav:

UNIS - Unilife Medical Solutions - Page 36

post #701 of 884
Quote:
Originally Posted by mxdave View Post



 

Quote:
Originally Posted by yojoe792 View Post

We aren't going to see a pre-earnings run-up because it's not profitable yet. 

 

Guys, this is a long term speculative play that you should put a LITTLE money in.  This isn't a "sleeping giant ready to wake up" or an "enormous buying opportunity."  

 

This is gonna be a crap stock until they get another deal.  Will they get another deal?  Maybe.  I don't know, you don't know, we don't know, they don't know.  That's where the speculation comes in.  Making money on this stock is going to either come through swing trades or luck.

 

Good luck to all.  Don't really see the need for all this activity here.  


Do some DD before you make any assumptions.You really have no idea what you are talking about.Visit the website and do some other looking into the company before you make random comments.Sure,it may not be moving as fast as anyone would want,but it is far from a "crap" stock.If you actually take the time to investigate it yourself you would see what others see.If you still think the way you do then fine,don`t waste your time posting back here.
 


You've tremendously misunderstood my post.  I own Unilife.  I've done my research and I really like its vision, I'm not here to bash.  Just offering my realist opinion.

 

All I'm saying is that UNIS, as somebody else mentioned, has been a crap stock for a good portion of the last year.  The market is up big, and Unilife is down big.  That's a crap stock.  It will continue to be a crap stock, in my opinion, until they get another deal or rumors of another deal arise.

 

I still like Unilife because I believe that this deal is going to happen at some point.  I just believe this isn't one of those companies that is just going to up all of a sudden on no news because some hedge fund discovers it.  I think the deal is going to come, but it's not a stock to get a continuous hard-on over.  Buy some, sit back, and hope for some returns.

post #702 of 884

Buy some, sit back, and hope for some returns.

 

I do agree with that.I misunderstood when you said crap stock.I took it as a crap company,which it is not.It has been a crap stock as far as perfomance in an up market.

post #703 of 884

Interestingly enough, this one is having another good day after yesterday's solid performance too.  I'll hold for now, but I'm going to cut it loose if it dips back below $5.

post #704 of 884

Guy's understand your stock.
It reached a very high unrealistic price early last year on hype. Probably market movers play... it follows some good theory on market manipulation papers posted on the web.
There was always going to be a quiet time while a state of the art manufacturing facility of this size was being built.
It only took 12 months to build even through some of the worst winter weather in that region.
Markets hate waiting, the market movers had a good time driving it down and taking position.
Give it six months, if UNIS don't make good with contracts sell!

The CEO has achieved a lot in the past 18 months and also surrounded himself with a very experienced team the last purchase proves this(COO & Exec VP, ex-BectonDixon big boy see welcome note).
All the boxes are slowly being ticked imo. No ramp, read doco's on their website.

Hold tight the next few months will be very exiting, it's all upward from here, with what's in place now.
Don't believe me, tune in to the webcast next week on the 14th for financials and updates, this should fill in some blanks.
:-)

post #705 of 884

Agreed.

post #706 of 884
Any predictions for earnings on Monday?
post #707 of 884
Quote:
Originally Posted by lmholmes11 View Post

Any predictions for earnings on Monday?



We may get a pullback to under 5 by then,but its really tough to gauge this one.Under 5 and I`m buying everything back that I sold at 5.20-5.24

post #708 of 884

I got out at $5.18 this morning, good luck to those of you who buy and hold.  I might grab this one on a dip once it turns into a solid uptrend, but I have no interest in watching it for now.  GL fellas!

post #709 of 884
Quote:
Originally Posted by jonebone View Post

I got out at $5.18 this morning, good luck to those of you who buy and hold.  I might grab this one on a dip once it turns into a solid uptrend, but I have no interest in watching it for now.  GL fellas!



 Its been like watching paint dry but I will buy back under 5 if it goes there.

post #710 of 884

So it seems the trick here is to buy @ 4.80 and then to sell at 5.15.  Pretty tight channel, especially given the low volume.  But I guess there's "some" money to be made here.

post #711 of 884
Quote:
Originally Posted by Quintious View Post

So it seems the trick here is to buy @ 4.80 and then to sell at 5.15.  Pretty tight channel, especially given the low volume.  But I guess there's "some" money to be made here.

I've been wanting to do this, but I'm always afraid that I'll sell at 5.15 and one day it'll finally go past 5.15 and not drop back down below 5.
 

post #712 of 884
Quote:
Originally Posted by klpv82 View Post



Quote:
Originally Posted by Quintious View Post

So it seems the trick here is to buy @ 4.80 and then to sell at 5.15.  Pretty tight channel, especially given the low volume.  But I guess there's "some" money to be made here.

I've been wanting to do this, but I'm always afraid that I'll sell at 5.15 and one day it'll finally go past 5.15 and not drop back down below 5.
 

Thats why I have holding positions and flipping positions.I`ve made enough flipping this that my hold shares are not only free but cash positive.

 

post #713 of 884

So is this where you pick it up for the swing trade?  I'm not touching this one again, but I have the trendline drawn right at the $4.65 level.  If it gets there, then the apparently strategy becomes grab it and dump it at $5.

post #714 of 884
Quote:
Originally Posted by jonebone View Post

So is this where you pick it up for the swing trade?  I'm not touching this one again, but I have the trendline drawn right at the $4.65 level.  If it gets there, then the apparently strategy becomes grab it and dump it at $5.


Would have been easy money, could have bought in at $4.65 yesterday and sold off at $5, all in one day!

post #715 of 884

Aussies didn't follow our lead yesterday, so UNIS has dropped to their closing price.

We follow.

Most of the stock is held over in Aus & traded(UNS) on their stock exchange, ASX, as CDIs(similar to ADRs), 6:1 ratio.

Apparently a lot of market maker play over there, trying to shake out the fragile holders, running through stops! Makes for a lot of uncertainty for new buyers.

 

Be good when all machine certs & validations are finished and production is under way.

Q2'11.....smile.gif

post #716 of 884

"Nice Shot" for Unilife (NASDAQ: UNIS) - The Scientist 2010


 

A well-articulated article in a January 2010 issue of “The Scientist” magazine, entitled “Nice Shot,” discusses a number of factors that have led to a dramatic wind shift favoring the vaccine segment of the pharmaceutical industry. The wind shift has caused the vaccine sector to go from unwanted orphan to beloved golden child. Increasing safety regulations imposed by the FDA, improving technologies, generic competition and eroding drug pipelines are the dynamics that are at the crux of vaccines’ growing market appeal.

With an expected growth rate of 14% over the next 4 years, the vaccine market is poised to be the fastest growing therapeutic area in the pharmaceutical industry. Worldwide sales of vaccines in 2007 were $18.5 billion and are expected to $35 billion by 2012. We are reminded of 2009, when governments around the world purchased $ 7 billion of H1N1 swine flu vaccines. The 5 pharmaceutical companies that serendipitously benefited from the flu epidemic included GlaxoSmithKline (NYSE: GSK), Novartis (NYSE: NVE), Sanofi-Aventis (SNY), AstraZeneca’s Medimmune (AZN), and CSL Limited, an Australian biopharmaceutical company.

The vaccine industry is dominated by Merck, GSK, Wyeth (purchased by Pfizer), Novartis and Sanofi-Aventis. In 2008, for example, vaccine sales exceeded pharmaceutical sales by a factor of more than three. At GlaxoSmithKline, specifically, vaccines have become the single greatest contributor to growth.

For a number of years, the drug pipeline well has been drying up. Traditional drug discovery programs have yielded few new products, and even fewer blockbuster drugs. Historically, pharmaceutical companies were able to bring new products to market whose innovative qualities led to commercial success. This has become exceedingly difficult. And then we have the proverbial “patent cliff.” By 2012, the pharmaceutical industry will have lost $67 billion in annual revenues to patent expiration of blockbuster drugs. Vaccines often circumvent the issue of generics as they are complex biological products requiring multimillion-dollar manufacturing facilities and in-depth manufacturing expertise. This is a major differentiating factor. Generic drug manufacturers tend to avoid knocking off vaccines due to these inherent difficulties. A dearth of generic competition equates to greater market longevity.

Unilife Corp (NASDAQ: UNIS) is a company that is poised to benefit from this seismic paradigm shift. The York, Pennsylvania –based company is the creator of the Unifill ready-to-fill prefilled syringe. Simply stated, a prefilled syringe is a single-dose packet of vaccine to which a needle has been fixed by the manufacturer. Addressing the $1.5 - $2 billion prefilled syringe market, the Unifill prefilled syringe offers distinct benefits over competitive prefilled syringes as they have safety features integrated within the glass barrel.

Prefilled syringes offer profound benefits which increases their appeal to pharmaceutical companies. For example, prefilled syringes can eliminate wastage during the filling process. Moreover, when compared to vials, they offer a simpler, faster and more reliable method of dose administration.

Growing at a significant rate, more than 2.5 billion prefilled syringes were used in 2010. Pharmaceutical manufacturers that need to comply with needlestick prevention laws in the U.S. and Europe must retrofit ancillary safety devices onto a standard syringe after dose filling and prior to packaging. In addition to the incremental steps and costs to the manufacturing process, the added bulk of these ancillary devices can add to packaging, transport and storage volumes by as much as 70%. By contrast, the Unifill syringe is similar in size to an equivalent standard prefilled syringe and is significantly smaller than those supplied with an ancillary safety device.

The Unifill ready-to-fill (prefilled) syringe is itself the primary drug container. However, as indicated above, unlike other prefilled syringes on the market, the Unifill includes passive (automatic) safety features that are fully integrated within the glass barrel. The product is ideal for use by healthcare workers or by patients who self-administer prescription medication while offering optimum protection from needlestick injuries.

One of the key benefits enjoyed by Unilife is their ability to help pharmaceutical companies optimize the lifecycle of new drugs. They are able to help bolster the competitive brand differentiation of drugs mid-way through their lifecycle by having them upgrade to the Unifill device. Unilife has commercial opportunities for several blockbuster drugs that are approaching patent expiration or that are coming under the threat of competition from biosimilar or generic drugs. Conversion of such blockbusters to Unifill products, which can be controlled within a particular therapeutic class and thus restricted to competitors, can provide a unique opportunity to enhance and even extend the lifecycle of the drug product. Potentially, the competitive advantages of the Unilife device within the drug-device combination product could even obstruct generic or biosimilar competition.

A major emerging trend within the pharmaceutical industry is the convergence of therapeutic drugs and innovative delivery devices. Unilife is uniquely positioned to capitalize upon this trend within the pharmaceutical market for prefilled syringes. This trend elevates Unilife to a new level beyond being a mere syringe story. By being able to offer pharmaceutical companies something more broad and enticing than a commoditized dose delivery mechanism, Unilife will effectively position itself to be produce a larger footprint in the healthcare industry. Their devices are unique and fully patented.

As testament to the commercial potential of the Unifill syringe, Unilife has a long-standing $40 million partnership with Sanofi-Aventis. Sanofi-Aventis is the world’s largest consumer of prefilled syringes. The $40 million that Unilife has received thus far was in exchange for certain exclusivities and industrialization milestones. That said, Unilife has openly stated on that they are in active discussions with a number of additional pharmaceutical companies interested in using the Unifill product in therapeutic areas outside of those retained by Sanofi-Aventis.

There are more than 20 pharmaceutical companies that utilize prefilled syringes as their device of choice for the administration of injectable drugs and vaccines. Furthermore, Unilife is tracking more than 80 marketed and pipeline drugs and vaccines that are considered potential candidates for the Unifill syringe. While most are pipeline drugs scheduled for launch between 2012 and 2015, many are already approved in a prefilled syringe format. One company in particular, for example, has advised Unilife that they have 13 drugs in the pipeline targeted for use with a prefilled syringe.
post #717 of 884

Looks appealing under $5, as always...

 

chart.ashx?t=UNIS&ty=c&ta=1&p=d&s=l

post #718 of 884

Sold.  Out.  Done.  I can't afford to keep watching Unilife stay flat during rallies and get pummeled during selloffs.  I'm going to keep it on my radar for sure and will get back in when I have some extra money to stash, but for now I've just had it.  I put it all in gold on Friday.  Good luck to all of you, I hope this thing works out for your sake. I'll check back in a few months.

post #719 of 884

Some News off the wire:

 

http://www.abc27.com/Global/story.asp?S=14181480&clienttype=printable

 

wink.gif

 

From the article:

Production at Unilife is expected to really pick up in about three months. That's when a big round of hiring is expected to happen. But company representatives said they are always looking for skilled workers and hard working people.

 

Contracts, contracts, contracts........3 months, sounds like it is still on target!

 

 

post #720 of 884

More news -

Unilife to Present at the 31st Annual Cowen Health Care Conference on Wednesday, March 9, 2011 in Boston
 
New Posts  All Forums:Forum Nav:
  Return Home
HotStockMarket › Forums › HSM Stock Forum › Stock Message Boards NYSE, NASDAQ, AMEX › UNIS - Unilife Medical Solutions